KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Cash & Equivalents (2016 - 2025)

Jazz Pharmaceuticals has reported Cash & Equivalents over the past 16 years, most recently at $1.4 billion for Q4 2025.

  • Quarterly results put Cash & Equivalents at $1.4 billion for Q4 2025, down 42.31% from a year ago — trailing twelve months through Dec 2025 was $1.4 billion (down 42.31% YoY), and the annual figure for FY2025 was $1.4 billion, down 42.31%.
  • Cash & Equivalents for Q4 2025 was $1.4 billion at Jazz Pharmaceuticals, up from $1.3 billion in the prior quarter.
  • Over the last five years, Cash & Equivalents for JAZZ hit a ceiling of $2.4 billion in Q4 2024 and a floor of $490.8 million in Q1 2022.
  • Median Cash & Equivalents over the past 5 years was $1.3 billion (2023), compared with a mean of $1.3 billion.
  • Biggest five-year swings in Cash & Equivalents: soared 198.96% in 2021 and later plummeted 76.6% in 2022.
  • Jazz Pharmaceuticals' Cash & Equivalents stood at $591.4 million in 2021, then surged by 49.04% to $881.5 million in 2022, then soared by 70.88% to $1.5 billion in 2023, then surged by 60.18% to $2.4 billion in 2024, then plummeted by 42.31% to $1.4 billion in 2025.
  • The last three reported values for Cash & Equivalents were $1.4 billion (Q4 2025), $1.3 billion (Q3 2025), and $1.2 billion (Q2 2025) per Business Quant data.